EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Genetic testing in autosomal dominant polycystic kidney disease: why it matters in 2025

Emilie Cornec-Le Gall iD, Albert C M Ong iD

Clinical Kidney Journal · 12.12.2025 · 18 (Supplement_2) · ii17-ii25

DOI: 10.1093/ckj/sfaf331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 31.10.2025. Verfasst von Emilie Cornec-Le Gall und 1 weiteren Autor:innen. Beteiligte Einrichtung: Service de Néphrologie, Hémodialyse et Transplantation Rénale, Centre de référence MARHEA, Filière ORKID, CHRU Brest, Brest, France. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of kidney failure globally, and a significant cause of morbidity and mortality. It is now recognized that it may result from both major and minor genes with associated differences in disease penetrance, symptom burden and clinical outcomes. Genetic testing is now readily available to discriminate between different genotypes and is being increasingly utilized for diagnostic and prognostic indications. In this short review, we summarize the reasons why testing should become part of standard care for ADPKD patients where available and highlight some current limitations and challenges to testing. Defining the genetic landscape in ADPKD for all ethnic groups will be key to the future development and deployment of individualized patient-centered management in this condition.

Schlagwörter

Stichwörter der Autor:innen

ADPKDgenetic testingprecision nephrologyprognosisvariant-specific therapy

Autor:innen und Institutionen

  • Service de Néphrologie, Hémodialyse et Transplantation Rénale, Centre de référence MARHEA, Filière ORKID, CHRU Brest, Brest, France.
  • University Brest, Inserm, UMR 1078, GGB, Brest, France.
  • Academic Nephrology, Department of Infection, Immunity and Cardiovascular Disease, Division of Clinical Medicine, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield, UK.
  • Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

ORCID-Profile: Emilie Cornec-Le Gall, Albert C M Ong

Zitieren

APA

Cornec-Le Gall, E., & Ong, A. C. M. (2025). Genetic testing in autosomal dominant polycystic kidney disease: why it matters in 2025. Clinical Kidney Journal, 18(Supplement_2), ii17-ii25. https://doi.org/10.1093/ckj/sfaf331

Vancouver

Cornec-Le Gall E, Ong ACM. Genetic testing in autosomal dominant polycystic kidney disease: why it matters in 2025. Clinical Kidney Journal. 2025;18(Supplement_2):ii17-ii25. doi:10.1093/ckj/sfaf331

BibTeX
@article{CornecLeGall2025,
  author = {Cornec-Le Gall, Emilie and Ong, Albert C M},
  title = {Genetic testing in autosomal dominant polycystic kidney disease: why it matters in 2025},
  journal = {Clinical Kidney Journal},
  year = {2025},
  volume = {18},
  number = {Supplement_2},
  pages = {ii17--ii25},
  doi = {10.1093/ckj/sfaf331}
}
Kostenlos starten →